ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 718,11
-0,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aclaris Therapeutics Inc (ACRS)

  7. Aclaris Therapeutics Inc (ACRS) Actualités

ACRS

Aclaris Therapeutics (ACRS)

Aclaris Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACRS
DateHeureSourceTitreSymboleSociété
07/05/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422h01GlobeNewswire Inc.Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
30/04/202413h00GlobeNewswire Inc.Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/04/202414h00PR Newswire (US)Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerNASDAQ:ACRSAclaris Therapeutics Inc
05/03/202423h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413h00GlobeNewswire Inc.Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
15/02/202402h32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
05/02/202422h31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
16/01/202413h00GlobeNewswire Inc.Aclaris Therapeutics Announces Leadership Changes and Strategic Business ReviewNASDAQ:ACRSAclaris Therapeutics Inc
10/01/202413h00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
19/12/202322h01GlobeNewswire Inc.Aclaris Therapeutics Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
05/12/202322h01GlobeNewswire Inc.Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaNASDAQ:ACRSAclaris Therapeutics Inc
13/11/202313h00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202313h00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/10/202322h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
03/10/202313h00GlobeNewswire Inc.Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)NASDAQ:ACRSAclaris Therapeutics Inc
20/09/202313h00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
18/09/202313h00GlobeNewswire Inc.Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorNASDAQ:ACRSAclaris Therapeutics Inc
07/08/202313h00GlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
22/06/202322h33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACRSAclaris Therapeutics Inc
20/06/202322h32Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ACRSAclaris Therapeutics Inc
13/06/202313h01GlobeNewswire Inc.Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)NASDAQ:ACRSAclaris Therapeutics Inc
12/06/202322h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRSAclaris Therapeutics Inc
02/06/202313h00GlobeNewswire Inc.Aclaris Therapeutics to Participate in Two June Healthcare Investor ConferencesNASDAQ:ACRSAclaris Therapeutics Inc
08/05/202322h06Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACRSAclaris Therapeutics Inc
08/05/202313h31Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACRSAclaris Therapeutics Inc
08/05/202313h00GlobeNewswire Inc.Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRS

Dernières Valeurs Consultées

EU
CAP
Capgemini
NYSE
KO
Coca Cola
NYSE
MCD
McDonalds
EU
HO
Thales
EU
ORA
Orange
EU
AI
Air Liquide
NASDAQ
AMZN
Amazon.com
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
NYSE
JPM
JP Morgan Chase
EU
RI
Pernod Ricard
FTSE
UKX
FTSE 100
NASDAQ
AAPL
Apple
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés